Table 1.
Demographics and clinical data of patients with AEDs-resistant epilepsy and patients with good response to AEDs.
| Clinical data | ADR | CTR |
|---|---|---|
| Age (years ± SD), range | 10.45 ± 3.762 (1–15) | 11.50 ± 3.017 (1–15) |
| Gender (F/M) | 12/8 | 3/3 |
| Onset of seizures | 4.715 ± 3.835 (1–14) | 4.833 ± 3.656 (2–10) |
| Number of seizures/month | 63.45 ± 27.76 (3–450) | – |
| Years of seizures | 5.85 ± 0.8438 (1–12) | – |
| Controlled time (years ± SD) range | – | 1.9 ± 0.28 (0.6–2) |
| Valproic Ac. dose (mg/day) | 598.0 ± 129.7 | 814.3 ± 212.1 |
| Valproic Ac. concentration/saliva (mg/l) | 0.57 ± 0.12 | 1.68 ± 0.59 |
| Valproic Ac. concentration/plasma (mg/l) | 31.62 ± 8.03 | 35.17 ± 18.04 |
| Carbamacepine dose (mg/day) | 900.0 ± 100.0 | 600.0 ± 200.0 |
| Carbamacepine concentration/saliva (mg/l) | 0.7244 ± 0.3232 | 1.017 ± 0.034 |
| Carbamacepine concentration/plasma (mg/l) | 5.900 ± 0.156 | 6.76 ± 0.29 |
| Phenytoin dose (mg/day) | 145.0 ± 55.00 | |
| Phenytoin concentration/saliva (mg/l) | 0.9337 ± 0.06814 | |
| Phenytoin concentration/plasma (mg/l) | 3.150 ± 1.750 | |
| Levetiracetam dose (mg/day) | 1250 ± 322.7 | 1000 ± 0.0 |
| Levetiracetam concentration/saliva (mg/l) | 1.661 ± 0.8825 | |
| Levetiracetam concentration/plasma (mg/l) | 4.657 ± 0.5897 |
Mean ± SD.
F, female; M, male.